

## Bioventus Names Alessandra Pavesio New Chief Science Officer

**DURHAM, N.C. – July 11, 2013** – Bioventus, a leader in active orthopaedic healing, today announced that Alessandra Pavesio will join the company Aug. 5 as its new Chief Science Officer. Pavesio will be based in the company's Durham headquarters and will report directly to Bioventus CEO Mark Augusti.

In the role, Pavesio, 46, will be responsible for providing critical strategic and operational leadership for the further growth of Bioventus products from early-stage development to commercial launch. She will lead various functional areas for the company including Research, Product Development, Clinical Affairs, Clinical Development, Project Management and Regulatory Affairs.

“As we work to expand our product portfolio and firmly establish our company as a leader in biologics, we knew it was crucial to have strong, experienced leadership in the CSO role,” Augusti said. “Alessandra’s technical knowledge, industry accomplishments and unwavering drive make her the ideal choice for the position. I’m excited to have her on our leadership team.”

During Pavesio’s 20-year career, she has developed – from concept to bedside – more than 25 Class-III innovative medical devices/biologics, designed for regeneration of soft and hard tissues, licensed to market leaders worldwide. A recognized opinion leader in regenerative medicine, Pavesio revolutionized cartilage regeneration by conceiving and developing the first third-generation autologous chondrocyte implantation technology to reach the market. She has also served as chairperson of international technology innovation platforms and government advisory councils.

Prior to joining Bioventus, Pavesio managed the Boston University Coulter Translational Partnership, a foundation-sponsored research program designed to enhance clinical impact and wealth creation through the development and transfer of innovative intellectual properties from university laboratories to commercial practice. She also held Vice President of Research & Development positions at two biomedical companies – Anika Therapeutics, a publicly-traded Massachusetts-based company that manufactures and markets products based on hyaluronic acid – and Fidia Advanced Biopolymers (FAB), a leading-edge European firm acquired by Anika

that specialized in hyaluronic acid-based regenerative medicine products for use in bio-orthopaedics, wound healing and specialty surgery.

Pavesio is the co-author of 25 peer reviewed publications and more than 15 patented inventions. She holds a Master's degree in Medicinal Chemistry from the University of Turin in Italy.

### ***About Bioventus***

Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company's innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine, and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

For more information, visit [www.BioventusGlobal.com](http://www.BioventusGlobal.com) or follow the company on Facebook ([www.facebook.com/bioventus](http://www.facebook.com/bioventus)) or Twitter (@BioventusGlobal or [www.twitter.com/BioventusGlobal](http://www.twitter.com/BioventusGlobal)).

### **Media Contact:**

Mike Truell  
Bioventus  
919-474-6755  
[michael.truell@BioventusGlobal.com](mailto:michael.truell@BioventusGlobal.com)

###